文献速递糖尿病

12-脂氧合酶抑制剂改善细胞因子处理的人胰岛及2型糖尿病胰岛功能

12-Lipoxygenase Inhibitor Improves Functions of Cytokine-Treated Human Islets and Type 2 Diabetic Islets.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

本研究为体外研究,使用非糖尿病供体人胰岛经肿瘤坏死因子α、白细胞介素-1β和干扰素-γ混合处理模拟胰岛炎症,并将细胞因子处理的胰岛及2型糖尿病供体胰岛在有或无ML355(高选择性小分子12-脂氧合酶抑制剂)条件下孵育。结果显示ML355可防止细胞因子处理的人胰岛胰岛素分泌和耗氧率下降,并改善2型糖尿病供体胰岛的上述两项参数。

要点

  • ML355可防止细胞因子处理的人胰岛胰岛素分泌和耗氧率下降。
  • ML355改善2型糖尿病供体人胰岛的胰岛素分泌和耗氧率。
  • 作者认为阻断12-脂氧合酶通路可能成为两型糖尿病的靶点,并为该小分子抑制剂的体内研究提供基础。

核心结论

  • ML355在体外可改善细胞因子处理后的人胰岛功能及2型糖尿病胰岛功能。
  • 作者认为阻断12-脂氧合酶通路可能成为两型糖尿病的靶点,并为该小分子抑制剂的体内研究提供基础。

研究设计与样本

  • 体外研究,使用年龄>20岁、不同性别和种族的器官捐献者人胰岛。
  • 非糖尿病供体人胰岛与肿瘤坏死因子α、白细胞介素-1β和干扰素-γ混合物孵育以模拟胰岛炎症。
  • 细胞因子处理的胰岛及2型糖尿病供体人胰岛在有或无ML355条件下孵育。
  • 2型糖尿病状态根据病史或最近一次糖化血红蛋白值>6.5%定义。
  • 干预为葡萄糖刺激,主要结局指标为静态和动态胰岛素分泌及耗氧率。

主要发现

  • ML355防止了细胞因子处理的人胰岛胰岛素分泌和耗氧率的降低。
  • ML355改善了2型糖尿病供体人胰岛的胰岛素分泌和耗氧率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The 12-lipoxygenase (12-LO) pathway produces proinflammatory metabolites, and its activation is implicated in islet inflammation associated with type 1 and type 2 diabetes (T2D). OBJECTIVES: We aimed to test the efficacy of ML355, a highly selective, small molecule inhibitor of 12-LO, for the preservation of islet function. DESIGN: Human islets from nondiabetic donors were incubated with a mixture of tumor necrosis factor α , interluekin-1β, and interferon-γ to model islet inflammation. Cytokine-treated islets and human islets from T2D donors were incubated in the presence and absence of ML355. SETTING: In vitro study. PARTICIPANTS: Human islets from organ donors aged >20 years of both sexes and any race were used. T2D status was defined from either medical history or most recent hemoglobin A1c value >6.5%. INTERVENTION: Glucose stimulation. MAIN OUTCOME MEASURES: Static and dynamic insulin secretion and oxygen consumption rate (OCR). RESULTS: ML355 prevented the reduction of insulin secretion and OCR in cytokine-treated human islets and improved both parameters in human islets from T2D donors. CONCLUSIONS: ML355 was efficacious in improving human islet function after cytokine treatment and in T2D islets in vitro. The study suggests that the blockade of the 12-LO pathway may serve as a target for both form of diabetes and provides the basis for further study of this small molecule inhibitor in vivo.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Ma K, Xiao A, Park SH, et al. 12-Lipoxygenase Inhibitor Improves Functions of Cytokine-Treated Human Islets and Type 2 Diabetic Islets. J Clin Endocrinol Metab. 2017. PMID: 28609824. doi:10.1210/jc.2017-00267

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。